摘要
客观的充血的心失败( CHF )是各种各样的心 diseases.Calcineurin ，由催化 subanit A ( CnA )组成的 calcium/calmodulindependent 磷酸酶和一个规章的钙绑定子单元的最后的普通小径 B ( CnB )，在学习试图与 CHF 在病人在心肌层在传播T淋巴细胞和那调查在 calcineurin 的 mRNA 水平之间的关系的心 failure.This 被激活。有 CHF 的 38 个病人全部的方法 A (从 29～62 年年老)在这 study.The mRNA 被包括 alpha 的层次--并且在左室的前面的乳突的肌肉和外部淋巴细胞的 CnA 的 beta-isoform 被半量的反向的抄写聚合酶链 reaction.Pearson 决定线性关联分析被执行，并且差别在 P 价值被认为统计上重要< 0.05 。在淋巴细胞的结果 Calcineurin mRNA 层次断然在心肌层与那些被相关(为 CnA-alpha mRNA ， r=0.820 ；为CnA贝它 mRNA ， r=0.875 ；两 P < 0.01 )在传播淋巴细胞和心肌层的.CnA贝它 mRNA 层次与增加 NYHA 班显著地增加了(为外部血的 r=0.877 和为心肌的 r=0.805 ；两 P < 0.01 )。在传播淋巴细胞的 CnA 贝它的 mRNA 水平断然在心肌层与那被相关并且是为在有 CHF 的病人的心脏的机能障碍的严厉的一个有希望的标记的结论。
Objective Congestive heart failure （CHF） is the final common pathway of various heart diseases.Calcineurin,a calcium/calmodulindependent phosphatase consisting of a catalytic subanit A （CnA） and a regulatory calcium-binding subunit B （CnB）,is activated in heart failure.This study aimed to investigate the relationship between mRNA level of calcineurin in circulating T-lymphocyte and that in myocardium in patients with CHF. Methods A total of 38 patients with CHF （aged from 29 to 62 years） were included in this study.The mRNA levels of alpha-and beta-isoform of CnA in left ventricular anterior papillary muscle and peripheral lymphocytes were determined by semi-quantitative reverse transcription polymerase chain reaction.Pearson linear correlation analysis was performed,and difference was considered statistically significant at a P value 〈0.05. Results Calcineurin mRNA levels in lymphocytes were positively correlated with those in myocardium （for CnA-alpha mRNA,r=0.820;for CnA-beta mRNA,r=0.875;both P〈0.01）.CnA-beta mRNA levels in both circulating lymphocytes and myocardium increased significantly with increasing NYHA class （r=0.877 for peripheral blood and r=0.805 for cardiac muscle;both P〈0.01）. Conclusions The mRNA level of CnA-beta in circulating lymphocytes is positively correlated with that in myocardium and is a promising marker for the severity of cardiac dysfunction in patients with CHF.
